Nurse-led program aims to boost survival and quality of life in lung cancer patients
NCT ID NCT05053997
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a nurse-led program that includes regular symptom check-ins, guidance, and exercise can improve survival and quality of life for 250 vulnerable lung cancer patients. Participants will be randomly assigned to receive this extra support or standard care. The goal is to help patients stick to their treatment and manage symptoms better.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- nurse navigation, symptom monitoring, and exercise program
- What this could lead to
- If successful, this approach could help vulnerable lung cancer patients live longer and feel better by improving treatment adherence and managing symptoms.
- What could go wrong
- This is a behavioral intervention, not a drug, so benefits may be modest. The trial is still recruiting and results are not yet available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years of age * Diagnosed with NSCLC at all stages regardless of treatment intension at the participating departments * Performance status ≤ 2 * Vulnerable according to pre-defined criteria Exclusion Criteria: * Severe untreated psychiatric disorder (e.g. psychosis) or cognitive problems (e.g. dementia) preventing informed consent * Not able to receive treatment * Not able to read and understand Danish -
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Aalborg University Hospital
RECRUITINGAalborg, Denmark
-
Gødstrup Hospital
RECRUITINGHerning, Denmark
-
Odense University Hospital
RECRUITINGOdense, Denmark
-
Sønderborg Sygehus
RECRUITINGSønderborg, Denmark
-
Vejle Sygehus
RECRUITINGVejle, Denmark
-
Zealand University Hospital
RECRUITINGRoskilde, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- Breath-Tracking sensor aims to sharpen lung cancer scans
- App aims to catch a hidden radiotherapy side effect